Literature DB >> 35323014

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!"

Mark S Butler1,2, Valeria Gigante3, Hatim Sati3, Sarah Paulin3, Laila Al-Sulaiman3, John H Rex4,5, Prabhavathi Fernandes6,7, Cesar A Arias8,9, Mical Paul10,11, Guy E Thwaites12,13, Lloyd Czaplewski14, Richard A Alm15, Christian Lienhardt16, Melvin Spigelman17, Lynn L Silver18, Norio Ohmagari19, Roman Kozlov20, Stephan Harbarth21,22, Peter Beyer3.   

Abstract

Entities:  

Year:  2022        PMID： 35323014      PMCID： PMC9017292          DOI： 10.1128/aac.00223-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  6 in total

1.  Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria.

Authors:  R K Flamm; D J Farrell; P R Rhomberg; N E Scangarella-Oman; H S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

2.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

3.  Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!

Authors:  Keith S Kaye; Adam Belley
Journal:  Antimicrob Agents Chemother       Date:  2022-03-24       Impact factor: 5.938

Review 4.  Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.

Authors:  Mark S Butler; Valeria Gigante; Hatim Sati; Sarah Paulin; Laila Al-Sulaiman; John H Rex; Prabhavathi Fernandes; Cesar A Arias; Mical Paul; Guy E Thwaites; Lloyd Czaplewski; Richard A Alm; Christian Lienhardt; Melvin Spigelman; Lynn L Silver; Norio Ohmagari; Roman Kozlov; Stephan Harbarth; Peter Beyer
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.191

Review 5.  Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.

Authors:  Nicole E Scangarella-Oman; Mohammad Hossain; Jennifer L Hoover; Caroline R Perry; Courtney Tiffany; Aline Barth; Etienne F Dumont
Journal:  Antimicrob Agents Chemother       Date:  2022-01-03       Impact factor: 5.191

6.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

Authors: 
Journal:  Lancet       Date:  2022-01-19       Impact factor: 202.731
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.